It is known that the so-called “post-COVID syndrome,” or the duration of symptoms of coronavirus disease, can last 12 weeks or more from the onset of the disease. The symptoms can occur from any system of the patient’s body, but most often it is the respiratory, cardiovascular, nervous and digestive systems.
Also among the symptoms of “post-COVID syndrome” are neurological disorders, such as prolonged weakness even after a mild course of the disease, sleep disturbances and severe weakness. Cognitive disorders are also common – impaired memory and functions of the higher nervous system.
Ukrainian experts and their colleagues from the EU in the United States recommend restorative therapy, physical rehabilitation, proper nutrition and normal sleep. Patients with clear complaints need additional examination and correction if necessary.
The Dnipro-Beskyd health resort became the first one in Truskavets where a comprehensive rehabilitation program after COVID-19 using unique mineral waters was developed and implemented.
Today, tens of thousands of Ukrainians suffer from post-COVID syndrome, many need long-term rehabilitation. The virus aggressively attacks the lungs, and complications can spread to the nervous, cardiovascular and digestive systems. Therefore, specialists from Dnipro-Beskyd together with scientists from the Ukrainian Research Institute of Medical Rehabilitation and Balneology of the Ministry of Health of Ukraine have developed effective methods that have already helped many return to normal life.
The rehabilitation program for patients with post-COVID syndrome in the Dnipro-Beskyd health and hotel complex is unique and exclusive, because only here there is an opportunity to conduct effective rehabilitation using Pomiretska Naftusya mineral water.
It has been known since 1836, has no analogues in the world, the composition of beneficial bacteria is ten times greater than in all existing analogues, while mineralization is much less, which allows faster digesting by the human body. It has been scientifically proven that Naftusya is the only “living water” in the world that strengthens human immunity. The healing properties of Naftusya were first described in the Ceplice works by royal (Polish) physician Wojciech Oczko in 1578. Water is received in the world’s first pump room with a contactless access system in Europe.
Also, only patients of Dnipro-Beskyd undergo rehabilitation with the use of natural hydrogen sulfide mineral water from well No. 123, one of the oldest sources, known since 1836.
During the baths, hydrogen sulfide enters the human body through the skin and mucous membranes, as well as through the lungs during respiration. As a result of its action, hydrogen sulfide normalizes blood pressure, increases blood flow and slows heart rate, improves metabolism, reduces the manifestations of various inflammatory processes, strengthens intervertebral cartilaginous discs, increases oxygen consumption and pulmonary ventilation. Hydrogen sulfide baths help normalize the immune and nervous systems. Patients become calm, their sleep and mood improve.
The use of unique mineral waters in combination with a modern medical and diagnostic base and highly qualified medical staff makes the program as effective as possible. This allows you to return to a normal lifestyle in the shortest possible time.
Patients who have already undergone the rehabilitation program note significant improvements, after the first days of treatment they can move without shortness of breath, cough decreases, sleep and general condition improve.
Rehabilitation is needed for patients with complaints of cough, poor sleep, fatigue, and cardiovascular disease. Specialists of Dnipro-Beskyd have developed an individual rehabilitation program for such patients. Those who have suffered from pneumonia are offered procedures to help repair the lungs affected by COVID-19.
The cost of the rehabilitation program includes accommodation, food, diagnosis and treatment, the cost of the program starts from UAH 720 per day, there are also promotional offers.
Find out more on the official website of the Dnipro-Beskyd health-hotel complex – https://beskyd.com.ua
An international research group consisting of 19 scientists from Germany, the U.K., Italy, the United States and Ukraine has published the results of a study of the effectiveness of the drug Amizon (active compound enisamium iodide) in the treatment of COVID-19 disease. The trials were carried out in-vitro (in laboratory). Its results are published on the Medrxiv website, which belongs to the Cold Spring Harbor Laboratory (the United States) and it is the world’s main resource providing open access to the results of research on COVID-19.
In their article, scientists from Institute of Medical Virology, University Hospital Frankfurt, Goethe University described for the first time the antiviral effect of Amizon against SARS-CoV-2. The co-authors of the article, scientists from Oxford and Cambridge Universities, have revealed the mechanism of action of the drug, which consists in inhibiting the viral RNA polymerase, under the influence of which the virus multiplies.
The results of the study made it possible to start the third stage of clinical trials of the drug in Ukraine. In May 2020, a multi-centre, randomized, double-blind, placebo-controlled study of the efficacy and safety of Amizon Max was launched. In the course of the study, the use of Amizon was combined with basic treatment of patients with moderate severity of COVID-19 infection.
The trials were carried out in parallel in several clinics in different cities of Ukraine. Specialists from Germany were involved in the study.
Intermediate results of the third stage of clinical trials of Amizon demonstrated its effectiveness in patients requiring non-invasive oxygen support (without the use of a ventilator). In particular, at this stage of the study, Amizon showed itself as a drug that accelerates the onset of a significant improvement in the condition of patients on average up to three days.
At the same time, to confirm or refute the positive trend, an additional recruitment of patients is currently being carried out to continue clinical trials. Final results are expected at the end of February.
The program “Treatment of Ukrainian citizens abroad” in the long term should be reduced to isolated cases, economist at the CASE Ukraine analytical center, author of a study on the implementation of the program and identification of more effective ways of state financing Natalia Leschenko has said.
“The program needs to be abandoned in the short term, but it requires tight budget constraints and prioritization of referrals for treatment (for example, referral to treatment of children, patients who have a high chance of returning to normal life). In the long term, the program needs to be reduced to isolated cases,” she said during a presentation of the study results on Tuesday.
Leschenko also said that it is necessary to introduce an assessment of the quality of such treatment.
“What would ideally like to see is an assessment of the patient’s health outcomes after treatment. The comparison of these results with the reference ones established on the basis of scientific research and clinical evaluations. This requirement is in the legislation of other countries that treatment abroad should be paid for at the state expense, only if this treatment is proven to be effective. Examples include readmission rates, mortality, complications,” she said.
“Our proposal is, in principle, not to increase funding for the program. The governments of most countries adhere to the principle of limited funding, that is, payment of a percentage of treatment or full payment to a limited number of people,” the expert said.
As reported, under the budget program “Treatment of Ukrainian citizens abroad” in 2020, UAH 1.089 billion is provided.
The Ministry of Health of Ukraine has created a separate unit, whose task will be the transplantation and treatment of Ukrainian patients abroad, the press service of the Ministry of Health reported on the Telegram channel.
“I want the number of Ukrainian patients who are being treated abroad to constantly decrease. I want them to be treated in Ukraine, to develop transplantation in Ukraine. We have everything for this. The main thing is that we have specialists who can transplant. We just need to create a certain system that would allow this to be done in Ukraine. We are doing this now,” Minister of Health Maksym Stepanov said at a daily briefing.
Pharmaceutical manufacturers of Ukraine register clinical trials of medicines for the treatment of coronavirus (COVID-19), Health Minister Maksym Stepanov has said.
“There are internal enterprises that register clinical trials of medicines, which they produce in our country. Currently, they are Farmak, Borschahivsky Chemical Pharmaceutical Plant, Darnitsa pharmaceutical company, Biopharma and Interchem. They are trying to create medicines to treat COVID-19, including symptomatic ones. For example, Darnitsa brought in a substance for the production of hydroxychloroquine, while Biopharma registered a clinical trial of Bioven,” he said during a press briefing in Kyiv on Wednesday, May 13.
It will become possible to resume treatment of Ukrainians abroad as soon as non-emergency care clinics open. All patients receive healthcare services at specialized clinics in Ukraine, Deputy Health Minister of Ukraine Iryna Mykychak told a press briefing in Kyiv on Thursday.
“There are patients who require medical services that are not available in Ukraine. This is, first of all, bone marrow transplant. The national budget provides for funds for treatment of such patients in foreign clinics. A standing commission, which makes decisions on referrals to treatment, is working. Currently foreign clinics are closed for non-emergency patients. As soon as they open, patients will be able to receive aid. Today they receive healthcare services at specialized clinics in Ukraine,” she said.